BRPI0820915A2 - método para expandir células tronco hematopoéticas usando composto heterocíclico - Google Patents

método para expandir células tronco hematopoéticas usando composto heterocíclico

Info

Publication number
BRPI0820915A2
BRPI0820915A2 BRPI0820915A BRPI0820915A BRPI0820915A2 BR PI0820915 A2 BRPI0820915 A2 BR PI0820915A2 BR PI0820915 A BRPI0820915 A BR PI0820915A BR PI0820915 A BRPI0820915 A BR PI0820915A BR PI0820915 A2 BRPI0820915 A2 BR PI0820915A2
Authority
BR
Brazil
Prior art keywords
stem cells
hematopoietic stem
heterocyclic compound
expanding hematopoietic
expanding
Prior art date
Application number
BRPI0820915A
Other languages
English (en)
Inventor
Miyaji Katsuaki
Yui Makiko
Ishiwata Norihisa
Iwamoto Shunsuke
Nishino Taito
Asai Yasuyuki
Original Assignee
Nissan Chemical Ind Ltd
Reprocell Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40717814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820915(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Ind Ltd, Reprocell Incorporated filed Critical Nissan Chemical Ind Ltd
Publication of BRPI0820915A2 publication Critical patent/BRPI0820915A2/pt
Publication of BRPI0820915A8 publication Critical patent/BRPI0820915A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0820915A 2007-12-06 2008-12-06 Método para expandir células-tronco hematopoéticas usando composto heterocíclico BRPI0820915A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007316276 2007-12-06
PCT/JP2008/072207 WO2009072635A1 (ja) 2007-12-06 2008-12-06 ヘテロ環化合物による造血幹細胞の増幅方法

Publications (2)

Publication Number Publication Date
BRPI0820915A2 true BRPI0820915A2 (pt) 2017-06-13
BRPI0820915A8 BRPI0820915A8 (pt) 2017-10-03

Family

ID=40717814

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820915A BRPI0820915A8 (pt) 2007-12-06 2008-12-06 Método para expandir células-tronco hematopoéticas usando composto heterocíclico

Country Status (10)

Country Link
US (1) US9527828B2 (pt)
EP (1) EP2218716B1 (pt)
JP (1) JP5663169B2 (pt)
CN (1) CN101889007A (pt)
AU (1) AU2008332303B2 (pt)
BR (1) BRPI0820915A8 (pt)
CA (1) CA2708050C (pt)
ES (1) ES2605611T3 (pt)
IL (1) IL206185A0 (pt)
WO (1) WO2009072635A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448949B (zh) * 2009-06-04 2014-09-03 日产化学工业株式会社 杂环化合物及造血干细胞的扩增剂
EP2647697B1 (en) 2010-12-01 2016-08-24 Nissan Chemical Industries, Ltd. Method for producing hematopoietic stem cells using pyrazole compound
RU2014117642A (ru) * 2011-10-03 2015-11-10 Ниссан Кемикал Индастриз, Лтд. Способ получения мегакариоцитов и/или тромбоцитов из плюрипотентных стволовых клеток
CN103740644B (zh) * 2013-03-20 2016-08-17 深圳爱生再生医学科技有限公司 一种基于3d培养体系的扩增造血干细胞的方法
ES2747951T3 (es) 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Método
CA3165561A1 (en) * 2020-01-24 2021-07-29 Satoshi Yamazaki Serum-free medium and culture method suitable for culturing blood cells including human hematopoietic stem cells
JP7891314B2 (ja) 2020-05-06 2026-07-16 セレクティス ソシエテ アノニム 治療用タンパク質の送達のために細胞を遺伝子改変する方法
WO2021224395A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
US11883436B2 (en) 2020-08-17 2024-01-30 The Board Of Trustees Of The University Of Illinois Method of preparing hematopoietic stem and progenitor cells for transplantation
US20240156872A1 (en) * 2021-01-13 2024-05-16 Albert Einstein College Of Medicine Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5605822A (en) 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US6326198B1 (en) 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5610056A (en) * 1994-11-16 1997-03-11 Amgen Inc. Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells
EP0870027A1 (en) * 1995-10-05 1998-10-14 G.D. Searle & Co. Novel c-mpl receptor agonists
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
JP3810273B2 (ja) 1998-02-17 2006-08-16 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
US6962698B1 (en) 1998-02-17 2005-11-08 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
JP2000023674A (ja) 1998-07-13 2000-01-25 Kirin Brewery Co Ltd 分化を抑制するペプチドと造血幹細胞増殖法
JP4453135B2 (ja) 1999-12-09 2010-04-21 東ソー株式会社 造血細胞の新規増幅剤
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
AU1091702A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded tpo agonist antibody
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
JP2004222502A (ja) 2003-01-17 2004-08-12 Asahi Kasei Corp 造血幹細胞増幅法
UA82695C2 (uk) 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JP4651282B2 (ja) * 2004-01-21 2011-03-16 田辺三菱製薬株式会社 造血幹細胞及び造血前駆細胞の増幅方法
TW200633998A (en) * 2004-12-08 2006-10-01 Nissan Chemical Ind Ltd Substituted heterocyclic compounds and thrombopoietin receptor activators
TW200633997A (en) * 2004-12-08 2006-10-01 Nissan Chemical Ind Ltd Substituted heterocyclic compounds and thrombopoietin receptor activators
KR101215207B1 (ko) 2004-12-14 2012-12-26 닛산 가가쿠 고교 가부시키 가이샤 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제
JP5071375B2 (ja) * 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
EP2006380A4 (en) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
KR20090021217A (ko) * 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제

Also Published As

Publication number Publication date
EP2218716A4 (en) 2012-07-25
EP2218716A1 (en) 2010-08-18
JPWO2009072635A1 (ja) 2011-04-28
IL206185A0 (en) 2010-12-30
US9527828B2 (en) 2016-12-27
AU2008332303A1 (en) 2009-06-11
CN101889007A (zh) 2010-11-17
WO2009072635A1 (ja) 2009-06-11
CA2708050C (en) 2016-08-16
EP2218716B1 (en) 2016-11-16
US20100266556A1 (en) 2010-10-21
AU2008332303B2 (en) 2014-02-13
ES2605611T3 (es) 2017-03-15
JP5663169B2 (ja) 2015-02-04
BRPI0820915A8 (pt) 2017-10-03
CA2708050A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
BRPI0921799A2 (pt) compostos que expandem células-tronco hematopoéticas
BRPI0917145A2 (pt) Método para fabricar biocombustíveis
BRPI0810558A2 (pt) Armazenador para transplante
IL206185A0 (en) Method for expanding hematopoietic stem cells using heterocyclic compound
BRPI0907608A2 (pt) Formulas dinâmicas para células de planilha
BRPI1014635A2 (pt) compostos heterocíclicos e de expansão para células-tronco hematopoiéticas
CR10781A (es) Medios disenado racionalmente para cultivo celular
BRPI0819127A2 (pt) Método para cimentar.
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
BRPI0822903A2 (pt) Autoconfiguração para células femto
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
FI20075721L (fi) Menetelmä pyrolysoinnin toteuttamiseksi
BRPI0921950A2 (pt) suporte para ferramentas
BRPI0823079A2 (pt) Unidade flutuante para aramazenamento de gás
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
EP2228435A4 (en) METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
EP2228434A4 (en) Amplification method for hematopoietic stem cells with heterocyclic compound
EP2233561A4 (en) METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
PT1901605E (pt) Meio de armazenagem para células
PT2214358T (pt) Método para o mapeamento de túneis
BRPI0908497A2 (pt) métodos e composições para um rendimento aumentado
FI20075264A0 (fi) Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina
EP2331676A4 (en) GROWTH FACTOR OF A HEMATOPOIETIC STEM CELL

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NISSAN CHEMICAL INDUSTRIES LTD (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.